Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Kohn

Showing results (101-110 of 369) with videos related to

Pageof 37
Sort By:
Bailliere'S Best Practice & Research. Clinical Obstetrics & Gynaecology|January 6, 2001
Angiogenesis in ovarian cancerM R Brown, J O Blanchette, E C Kohn
Experimental Cell Research|July 10, 1997
Regulation of cellular tyrosine phosphorylation by stimulatory and inhibitory muscarinic acetylcholine receptorsR Alessandro, A Pugnaloni, G Biagini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 15, 2013
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignanciesJ-M Lee, J A Ledermann, E C Kohn
Cancer|December 15, 2023
Top advances of the year: Ovarian cancerMelissa A Lumish, Elise C Kohn, William P Tew
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 2, 2016
Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair DeficiencyRebecca S Kristeleit, Rowan E Miller, Elise C Kohn
Trends in Cancer|July 26, 2017
The 'Pushmi-Pullyu' of DNA REPAIR: Clinical Synthetic LethalityS Percy Ivy, Johann de Bono, Elise C Kohn
Cancer Research|June 1, 1992
In vivo efficacy of a novel inhibitor of selected signal transduction pathways including calcium, arachidonate, and inositol phosphatesE C Kohn, M A Sandeen, L A Liotta
American Journal of Pharmacogenomics : Genomics-Related Research in Drug Development and Clinical Practice|June 15, 2005
Applying proteomics in clinical trials: assessing the potential and practical limitations in ovarian cancerNana E Tchabo, Meghan S Liel, Elise C Kohn
JAMA|November 17, 2001
Clinical proteomics: personalized molecular medicineL A Liotta, E C Kohn, E F Petricoin
Risk Analysis : an Official Publication of the Society for Risk Analysis|December 1, 1994
The importance of biological realism in dioxin risk assessment modelsM C Kohn, G W Lucier, C J Portier
Pageof 37

Showing results (101-110 of 369) with videos related to

Sort By:
Pageof 37
Bailliere'S Best Practice & Research. Clinical Obstetrics & Gynaecology|January 6, 2001
Angiogenesis in ovarian cancerM R Brown, J O Blanchette, E C Kohn
Experimental Cell Research|July 10, 1997
Regulation of cellular tyrosine phosphorylation by stimulatory and inhibitory muscarinic acetylcholine receptorsR Alessandro, A Pugnaloni, G Biagini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 15, 2013
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignanciesJ-M Lee, J A Ledermann, E C Kohn
Cancer|December 15, 2023
Top advances of the year: Ovarian cancerMelissa A Lumish, Elise C Kohn, William P Tew
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 2, 2016
Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair DeficiencyRebecca S Kristeleit, Rowan E Miller, Elise C Kohn
Trends in Cancer|July 26, 2017
The 'Pushmi-Pullyu' of DNA REPAIR: Clinical Synthetic LethalityS Percy Ivy, Johann de Bono, Elise C Kohn
Cancer Research|June 1, 1992
In vivo efficacy of a novel inhibitor of selected signal transduction pathways including calcium, arachidonate, and inositol phosphatesE C Kohn, M A Sandeen, L A Liotta
American Journal of Pharmacogenomics : Genomics-Related Research in Drug Development and Clinical Practice|June 15, 2005
Applying proteomics in clinical trials: assessing the potential and practical limitations in ovarian cancerNana E Tchabo, Meghan S Liel, Elise C Kohn
JAMA|November 17, 2001
Clinical proteomics: personalized molecular medicineL A Liotta, E C Kohn, E F Petricoin
Risk Analysis : an Official Publication of the Society for Risk Analysis|December 1, 1994
The importance of biological realism in dioxin risk assessment modelsM C Kohn, G W Lucier, C J Portier
Pageof 37